英国批准Wegovy用于减轻超重成人心脏风险. UK approves Wegovy for heart risk reduction in overweight adults.

英国卫生监管机构NICE建议诺沃北方公司的Wegovy降低超重成人心脏风险,使其成为英国首个批准用于此目的GLP-1药物. The UK's health regulator, NICE, has recommended Novo Nordisk's Wegovy for reducing heart risks in overweight adults, making it the first GLP-1 drug approved for this purpose in the UK. 根据一项研究显示,2. 4毫克剂量可通过国家卫生服务获得,该药物减少了20%的重大心血管事件. The 2.4-milligram dose will be available through the National Health Service, following a study showing a 20% reduction in major cardiovascular events.